May 15th 2024
New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.
May 13th 2024
The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.
April 30th 2024
People with diabetes exhibit significantly greater odds of developing carpal tunnel syndrome compared with non-diabetic individuals.
The HCPLive Endocrinology month in review for April 2024 spotlights SURMOUNT-OSA, STEP HFpEF DM, new ACP guidelines for T2D, and more!
April 25th 2024
A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
Intestinal Viruses Appear to Correlate with T1D Risk
The viruses in a child’s intestines may hold clues about how likely the child is to eventually develop T1D, according to a new study.
FDA Investigation of Lead-Testing Facility Uncovers Several Potential Federal Violations
The FDA is encouraging healthcare providers to retest patients tested for lead exposure with Magellan Diagnostics devices.
Patients with Diabetes Often Readmitted for Hypo- and Hyperglycemia
Some hospital readmissions may be avoided for diabetic hypoglycemia and hyperglycemia cases with better follow-up care.
What to Look for in an Electronic Medical Records System
Haven't switched to an electronic health record system yet? endocrinologist Melissa Young, MD has a few tips on getting started.
5 Top EMRs for Endocrinologists
Click through a short list of electronic medical records ranked highly for endocrinology practices.
Eliminating Hepatitis C with Antiviral Drugs Improves Diabetes Control, Study Finds
Eradicating the hepatitis C virus (HCV) with direct-acting antiviral (DAA) drugs improves the control of glucose levels in patients with type 2 diabetes (T2D), a new study suggests.
Organ Donors with Type 1 Diabetes Show High Rates of Illicit Drug Abuse
Patients with T1D should be screened for depression and diabetes-related distress.
FDA Expands Approval of CoreValve Evolut TAVR Platform
The FDA expanded approval of a self-expanding TAVR platform to include patients who are at an intermediate risk for open-heart surgery.
Empagliflozin Shows Benefits on Albuminuria
The EMPA-REG OUTCOME trial shows short- and long-term benefits of empagliflozin on albuminuria in patients with T2D and CVD.
Novo Nordisk Issues Voluntary Recall of Cartridge Holders in Some Insulin Delivery Devices
A small number of NovoPen Echo devices may crack or break if exposed to certain chemicals.
Can Weight Loss in Youth Reduce Risk of Type 2 Diabetes?
New research suggests it’s possible to reverse the metabolic impact of childhood obesity and avert T2DM in adulthood.
Results from SWITCH Trials Published
The drug reduced risk of overall symptomatic hypoglycemia compared to insulin glargine U100.
DPP: Lifestyle Change Reduces Risk of Progression to Diabetes
Weight loss achieved through improved diet and increased physical activity is the key--but how much?
Liraglutide, and the Link Between Diabetic and Cardiovascular Care
What the Type 2 diabetes treatment could do if approved for cardiovascular events, according to Karol Watson, MD.
Incretin-Based Treatments: No Evidence of Rise in All-Cause Mortality for Patients with Type 2 Diabetes?
A meta-analysis provides no support for theory that incretin-based treatment causes increased mortality in patients with T2D.
Weekly Albiglutide Found Equal to Thrice-Daily Insulin for Treatment-Refractory Type 2 Diabetes
Glucose was controlled as well with weekly injections of albiglutide as with 3-times daily prandial insulin lispro.
Heart Failure Medications Evaluated for Effects on Comorbid Diabetes
Modified Starch Found in Foods Prevents Diabetes in Early Studies
High-amylose maize starch with chemical add-ons prevented diabtes in susceptible mice in an Australian study.
Anacetrapib Meets Primary Endpoint, But Its Future is Called Into Question
Despite its recent success, Morgan Stanley experts give the drug 5% odds of reaching markets.
Beta Blockers Heighten Risk of CV Events in T2DM
Post-hoc analysis of ACCORD trial data suggests the indication of beta blocker therapy in T2DM patients be more closely examined.
Diabetes Add-On Treatments Vary in Kidney Care
Pioglitazone actions on reducing insulin resistance could mediate changes in renal function.
The Top 10 Stories of June 2017
A look back at what studies, headlines, and news caught our readers' eyes most throughout the month.
Diabetes News Roundup: New Thoughts on Standard Thinking
Find research on diabetes patients that could shift your thinking on home blood glucose monitoring; metformin efficacy in T1DM; and race and A1c.
7 FDA Approvals You Need to Know
Plus a "Better Care Reconciliation Act" wrap up and 2 bonus approvals from across the pond.
Novartis' Canakinumab Meets Endpoint in Phase III CANTOS Trial
The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.
Artificial Pancreas Hybrid Closed-loop Systems: Easing Diabetes' Burden
EMDAC Recommends Liraglutide's Approval to Reduce CV Risk in T2D Patients
Novo Nordisk seeks broad primary prevention claim, EMDAC recommends drug for patients with established CV.
Safety Benefits, Risks of Canafliglozin for Type 2 Diabetes
The CANVAS results yield promise against cardiovascular events, but a risk of amputations.
Helping Youth with Type 1 Diabetes Improve Transition from Pediatric to Adult Care
Access to a transition coordinator benefited youths with T1D during their transition period.
Continuous Glucose Monitoring for Type 1 Diabetes
William Polonsky, PhD, CDE, explains where more benefits lie in T2D patients using the monitoring devices.